10-Q: Predictive Oncology Pivots to Crypto, Reports Massive Loss

Predictive Oncology Inc. reported a significant net loss of $82.17 million for the nine months ended September 30, 2025, driven by a $74.37 million derivative liability related to its new Aethir token (ATH) treasury strategy, while securing $50.8 million in cash and $173.3 million in ATH through private placements post-period.

Summary

• The company reported a net loss of $77.65 million for the three months ended September 30, 2025, and $82.17 million for the nine months ended September 30, 2025, a substantial increase from $3.09 million and $10.49 million in the comparable 2024 periods, respectively.
• The significant increase in net loss is primarily due to a $74.37 million loss on derivative instruments related to the Crypto PIPE Offering entered into on September 29, 2025.
• Total current liabilities surged to $79.49 million as of September 30, 2025, from $3.59 million at December 31, 2024, largely due to the $74.37 million derivative liability.
• The company's accumulated deficit increased to $262.59 million as of September 30, 2025, from $180.43 million at December 31, 2024.
• Cash and cash equivalents decreased to $181,667 as of September 30, 2025, from $611,822 at December 31, 2024.
• Revenue from continuing operations for the nine months ended September 30, 2025, increased to $116,610 from $76,020 in the prior year, primarily due to the completion of a tumor-specific 3D model.
• The company adopted a new digital asset treasury strategy focused on the Aethir token (ATH) to create a Strategic Compute Reserve, functioning as an operator on the Aethir network.
• Post-period, on October 7, 2025, the company closed two private placements, raising approximately $50.8 million in cash and receiving ATH tokens with a discounted value of approximately $173.3 million.
• As of November 10, 2025, the company held approximately 5.70 billion ATH tokens, with a market value of approximately $152.8 million, of which 3.7 billion are locked and 2.0 billion are unlocked.
• The company completed a one-for-fifteen reverse stock split on September 29, 2025, which became effective for trading purposes on September 30, 2025.
• The reverse stock split helped the company regain compliance with Nasdaq's Minimum Bid Price Requirement, confirmed on October 14, 2025.
• The company disposed of its former Eagan operating segment (STREAMWAY product line) for $625,000 on March 14, 2025, reclassifying it as discontinued operations.
• A lawsuit was filed by Renovaro, Inc. on May 8, 2025, claiming breaches of a terminated Letter of Intent regarding a proposed merger, which the company is vigorously contesting.

Sentiment

Score: 3

Explanation: The company reported a significantly increased net loss and accumulated deficit, primarily due to a large non-cash derivative liability. While substantial capital was raised post-period and Nasdaq compliance was regained, the strategic pivot to a highly volatile digital asset treasury introduces significant new risks and uncertainties, overshadowing the core oncology business and leading to a cautious outlook.

Positives

• Successfully raised approximately $50.8 million in cash and $173.3 million in Aethir tokens (ATH) through private placements that closed on October 7, 2025, significantly improving liquidity.
• Regained compliance with Nasdaq's Minimum Bid Price Requirement on October 14, 2025, following a one-for-fifteen reverse stock split.
• Net cash used in continuing operating activities decreased to $5,934,497 for the nine months ended September 30, 2025, from $8,049,679 in the prior year, indicating improved operational cash efficiency.
• Revenue from continuing operations increased by $40,590 to $116,610 for the nine months ended September 30, 2025, compared to the same period in 2024.
• The company believes its working capital and cash position will be sufficient to fund operations for at least 12 months following the October 2025 capital raises.

Negatives

• Reported a substantial net loss of $82,165,178 for the nine months ended September 30, 2025, a significant increase from $10,494,794 in the prior year, primarily due to a non-cash derivative liability.
• Accumulated deficit grew significantly to $262,591,449 as of September 30, 2025, from $180,426,271 at December 31, 2024.
• Total current liabilities increased dramatically to $79,488,676 as of September 30, 2025, from $3,593,401 at December 31, 2024, mainly due to a $74,366,000 derivative liability.
• Cash and cash equivalents decreased to $181,667 as of September 30, 2025, from $611,822 at December 31, 2024, prior to the October 2025 capital raises.
• The company was notified of non-compliance with Nasdaq's minimum stockholders' equity requirement and received a delisting notice on June 9, 2025, requiring an extension to regain compliance.
• A lawsuit was filed by Renovaro, Inc. on May 8, 2025, alleging breach of contract and seeking to compel a merger, creating legal uncertainty and potential costs.

Risks

• The common stock could be delisted from the Nasdaq Capital Market if the company fails to comply with all continued listing requirements by December 8, 2025.
• The lawsuit filed by Renovaro, Inc. could be costly and time-consuming, potentially impacting financial condition and results of operations.
• The price of Aethir tokens (ATH) is highly volatile and unpredictable, which could lead to significant fluctuations in operating results and share price.
• The company may be unable to successfully implement its new digital asset treasury strategy, which requires specialized skillsets and operational infrastructure.
• The shift towards an Aethir-focused strategy exposes the company to significant operational risks, including network upgrades, lock-up periods for staked assets, and reliance on third-party service providers.
• The concentration of ATH holdings limits risk mitigation and enhances the impact of adverse developments specific to ATH or its network.
• Disruptions to the Aethir network (insolvency, security breaches, network outages, competition) could negatively impact the value of ATH.
• ATH and other digital assets are subject to significant legal, commercial, regulatory, and technical uncertainty, including potential classification as securities or commodities, which could lead to increased compliance costs or operational shutdowns.
• Interaction with smart contracts on the Aethir network exposes the company to risks of technical vulnerabilities, coding errors, security flaws, and exploitation attacks.
• Future acquisitions in the Aethir-focused or blockchain space carry integration risks and may not be successfully completed or integrated.
• The company's ability to achieve its business strategy depends on obtaining equity and debt financing, which may not be available on favorable terms or at all.
• Changes in regulatory interpretations could require the company to register as a money services business or money transmitter, leading to increased compliance costs or operational shutdowns.
• If digital assets held are classified as securities, the company may be subject to extensive regulation under the Securities Act or Investment Company Act of 1940, potentially forcing it to cease operations.
• If digital assets held are classified as commodities, the company could be subject to additional CFTC regulation, resulting in significant compliance costs or cessation of operations.
• Changes in tax treatment of rewards from staking ATH could lead to additional tax liabilities.
• The company is not subject to legal and regulatory obligations that apply to investment companies or investment advisers, meaning shareholders lack certain protections.
• Digital asset trading venues experience greater risk of fraud, market manipulation, security failures, or regulatory problems compared to traditional markets.
• Historical financial statements do not reflect the potential variability in earnings from digital asset holdings, making future profitability difficult to predict.
• Digital asset holdings are less liquid than cash and cash equivalents and may not serve as a reliable source of liquidity during market instability.
• The availability of spot exchange-traded products for digital assets may adversely affect the market price of the company's listed securities.
• Digital asset lending arrangements (if pursued) may expose the company to risks of borrower default, operational failures, and cybersecurity threats.
• Decentralized finance arrangements (if pursued) may expose the company to risks of smart contract flaws, operational failures, and cybersecurity threats.
• Reliance on open-source code by digital asset networks exposes the company to risks related to competitive networks, maintenance failures, and security vulnerabilities.
• The lack of legal recourse and insurance for digital assets increases the risk of total loss in the event of theft or destruction.
• The company faces risks relating to the custody of its digital assets, including security breaches, cyberattacks, loss of private keys, and custodian insolvency.
• Risks relating to the use of third-party trading platforms in connection with the Aethir-focused strategy, including counterparty risk and compliance.
• The irreversibility of digital asset transactions exposes the company to risks of theft, loss, and human error.
• Significant competition in the growing digital asset industry, including from other companies with ATH holdings and emerging blockchain protocols.
• Aethir is subject to technological obsolescence and competition from emerging blockchain and artificial intelligence protocols.
• A cyberattack or other malicious attack on the Aethir network could materially impact the value of ATH.
• The emergence or growth of other digital assets, including those with significant private or public sector backing (e.g., CBDCs, stablecoins), could negatively impact the price of ATH.
• Loss of key personnel or the Asset Manager (DNA) could impair the ability to operate and manage the Treasury Strategy.

Future Outlook

The company intends to continue acquiring additional Aethir tokens (ATH) in the open market and earn yield on its ATH treasury holdings through staking and other activities. Net cash proceeds from recent private placements will primarily fund ATH acquisition and general corporate purposes. The company believes its current working capital and cash position, bolstered by recent financings, will be sufficient to fund ongoing operations for at least 12 months. Future cash requirements depend on generating revenue from oncology drug discovery, income from the Treasury Strategy, and availability of future financing.

Management Comments

• Management is focusing resources on the Treasury Strategy, and a significant portion of the balance sheet will be allocated to holding ATH.
• The company believes that its working capital and cash position will be sufficient to fund its on-going operations for a period of at least 12 months subsequent to the issuance of these condensed consolidated financial statements.
• The company does not believe the Renovaro lawsuit has merit and continues to contest it vigorously.

Industry Context

Predictive Oncology is pivoting its strategy from solely AI-driven cancer therapy discovery to include a significant digital asset treasury strategy focused on Aethir tokens (ATH). This move positions the company within the rapidly evolving decentralized physical infrastructure network (DePIN) and AI infrastructure sectors, where ATH functions as a utility token for GPU rentals and network rewards. This shift aligns with broader trends of companies exploring digital assets for treasury management and leveraging decentralized networks for compute power, but also exposes the company to the nascent and highly volatile cryptocurrency market, a significant departure from its traditional biotech focus.

Comparison to Industry Standards

• The company's pivot to a digital asset treasury strategy, particularly with a high concentration in a single digital asset like ATH, is a non-standard approach for a publicly traded oncology drug discovery company. Traditional biotech companies typically focus on R&D, clinical trials, and market penetration, with treasury management in conventional financial instruments.
• The reported net loss of $82.17 million for nine months, largely driven by a derivative liability, is significantly higher than typical operating losses for a company of its size in either the biotech or early-stage crypto operator space, though the derivative liability is a non-cash accounting item related to the structure of the crypto private placement.
• The capital raise of $50.8 million in cash and $173.3 million in ATH is substantial for a company of this market capitalization, reflecting a significant re-capitalization and strategic shift, which is not directly comparable to standard biotech funding rounds or typical crypto project financing due to the hybrid nature of the company's new strategy.

Management Changes

Corporate Governance

Legal Proceedings

• On May 8, 2025, Renovaro, Inc. filed a lawsuit in Delaware Chancery Court against the company, claiming breaches of the Letter of Intent and Extension Agreement related to a proposed merger and seeking to compel the company to enter into a merger agreement. The company does not believe the lawsuit has merit and is contesting it vigorously. The final outcome cannot be predicted with certainty, and unfavorable developments could materially impact financial condition and results of operations.

Related Party Transactions

• The company entered into a Strategic Advisor Agreement and an Asset Management Agreement with DNA Holdings Venture, Inc. (DNA) on October 7, 2025. Shawn Matthews, CEO of DNA, was appointed to the company's Board of Directors on September 26, 2025. As compensation under the Strategic Advisor Agreement, the company issued warrants to DNA to purchase up to 1,348,906 shares of common stock. Under the Asset Management Agreement, DNA is entitled to a 1.00% per annum asset-based management fee plus an incentive fee of 25% of profits earned on managed assets over 7%.

Stakeholder Impact

• Shareholders: Experienced significant dilution from multiple equity offerings and a reverse stock split. Face substantial risks and potential volatility due to the new digital asset treasury strategy. The large net loss and accumulated deficit could concern investors, though the post-period capital raise provides liquidity.
• Employees: The company's strategic pivot to digital assets may shift focus and resource allocation, potentially impacting roles and opportunities within the traditional oncology drug discovery segment.
• Customers (Oncology Drug Discovery): The company continues its AI-driven oncology drug discovery business, but the primary focus of management and balance sheet allocation is now on the digital asset strategy, which could affect the pace or investment in this segment.
• Creditors: The significant increase in total liabilities, driven by the derivative liability, and the accumulated deficit indicate a challenging financial position, though the recent capital raise improves short-term liquidity.

Next Steps

• Continue acquiring additional Aethir tokens (ATH) in the open market to build the Strategic Compute Reserve.
• Earn yield on ATH treasury holdings by engaging in ATH staking and other activities.
• Manage the digital asset treasury through DNA Holdings Venture, Inc. under the Asset Management Agreement.
• Address the ongoing lawsuit filed by Renovaro, Inc. vigorously.
• Maintain Nasdaq listing compliance, particularly the stockholders' equity requirement by the December 8, 2025 deadline.
• File a registration statement on Form S-1 or S-3 for the resale of shares issued in the August 2025 private placement and the September 2025 private placements.
• Implement the new accounting standard ASU 2023-09 for income tax disclosures, effective for fiscal years beginning after December 15, 2024.
• Evaluate the impact of ASU 2024-03 on income statement expense disclosures, effective for fiscal years beginning after December 15, 2026.

Key Dates

Recommendation

Predictive Oncology Inc. is undergoing a radical strategic pivot from AI-driven oncology to a digital asset treasury strategy, primarily focused on Aethir tokens. While the company successfully raised significant capital post-period ($50.8 million cash and $173.3 million in ATH) and regained Nasdaq compliance, the reported net loss of $82.17 million for the nine months ended September 30, 2025, driven by a large non-cash derivative liability, highlights extreme financial volatility. The new strategy introduces substantial, unproven risks associated with cryptocurrency market volatility, regulatory uncertainty, operational complexities of decentralized networks, and potential dilution. The ongoing lawsuit with Renovaro adds further uncertainty. Given the high-risk, high-reward nature of this pivot and the significant uncertainties, a 'hold' recommendation is appropriate for existing investors to observe the execution of the new strategy and its impact on financial performance and risk profile. New investors should exercise extreme caution due to the speculative nature of the new business model and the inherent risks of digital assets.

Keywords

Aethir token, ATH, digital asset treasury, cryptocurrency, AI drug discovery, oncology, SEC filing, 10-Q, Predictive Oncology, POAI, reverse stock split, Nasdaq compliance, private placement, derivative liability, corporate governance, risk management, financial reporting, biotechnology, decentralized physical infrastructure network, GPU network, staking